Recursion Pharmaceuticals (RXRX) Revenue (2020 - 2026)

Recursion Pharmaceuticals' Revenue history runs 7 years deep, the most recent figure standing at $6.5 million for Q1 2026.

• Quarterly Revenue fell 56.11% year-over-year to $6.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $66.4 million (up 11.07% YoY) and the FY2025 annual result came in at $74.7 million, up 26.92% from the prior year.
• Revenue was $6.5 million for Q1 2026 at Recursion Pharmaceuticals, down from $35.5 million in the prior quarter.
• Across five years, Revenue topped out at $35.5 million in Q4 2025 and bottomed at $4.5 million in Q4 2024.
• A 5-year average of $13.2 million and a median of $12.1 million in 2023 frame the typical range for Revenue.
• Peak annual rise in Revenue reached 681.74% in 2025, while the deepest fall reached 80.16% in 2025.
• Recursion Pharmaceuticals' Revenue stood at $13.7 million in 2022, then slipped by 20.36% to $10.9 million in 2023, then slumped by 58.26% to $4.5 million in 2024, then jumped by 681.74% to $35.5 million in 2025, then tumbled by 81.79% to $6.5 million in 2026.
• Business Quant data shows RXRX's Revenue at $6.5 million in Q1 2026, $35.5 million in Q4 2025, and $5.2 million in Q3 2025.